Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition Amplification in a Lung Cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase Fusion Gene-Reference-Cited by-同舟云学术

Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition Amplification in a Lung Cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase Fusion Gene

Published:2023-11-01 Issue:21 Volume:62 Page:3215-3221
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Shiraishi Tomoko¹,Yamasaki Kei¹,Kidogawa Moe¹,Shingu Tatsuya¹,Ujimiya Fuki¹,Jotatsu Takanobu¹,Matsumoto Shingo²,Izumi Hiroki²,Nishida Chinatsu¹,Goto Koichi²,Yatera Kazuhiro¹

Affiliation:

1. Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan

2. Department of Thoracic Oncology, National Cancer Center Hospital East, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/62/21/62_1164-22/_pdf

Reference38 articles.

1. 1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566, 2007.

2. 2. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 4: 120ra17, 2012.

3. 3. Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 6: 1118-1133, 2016.

4. 4. Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376: e768-e771, 1995.

5. 5. Sattler M, Salgia R. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep 9: 102-108, 2007.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antineoplastics;Reactions Weekly;2023-12-23

2. Combinatorial therapy is a safe and durable treatment option in ALK-rearranged non-small cell lung cancer with an acquired MET exon 14 skipping mutation mediated resistance to alectinib: a case report;Translational Lung Cancer Research;2023-12

3. Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms;Frontiers in Pharmacology;2023-10-25